Primary and secondary thrombocytosis in childhood

Area of Science:

• Pediatric Hematology
• Oncology
• Molecular Genetics

Background:

• Thrombocytosis, characterized by elevated platelet counts, can be primary (essential) or secondary (reactive).
• Understanding the underlying pathomechanisms and clinical manifestations is crucial for appropriate management in children.
• Primary thrombocytosis in childhood is rare, often presenting in adolescence, while secondary thrombocytosis is more common.

Purpose of the Study:

• To review current data on the pathomechanisms and clinical aspects of primary and secondary thrombocytosis in childhood.
• To delineate diagnostic criteria and treatment strategies for pediatric thrombocytosis.

Main Methods:

• Literature review of pathomechanisms and clinical data on childhood thrombocytosis.
• Analysis of diagnostic criteria, including those for Polycythemia Vera Group.
• Evaluation of treatment recommendations and risk-benefit assessments for therapeutic interventions.

Main Results:

• Primary thrombocytosis in children is rare, with non-familial forms involving megakaryopoietic progenitors and thrombopoietin (Tpo) sensitivity, and familial forms linked to Tpo or c-mpl gene mutations.
• Treatment for primary thrombocytosis is generally not advised unless platelet counts exceed 1500/nl with a history of bleeding or thrombosis.
• Secondary thrombocytosis is frequent, driven by hepatic Tpo production in response to various disorders; thrombosis prophylaxis is typically not needed unless additional risk factors are present.

Conclusions:

• Primary thrombocytosis in children requires careful diagnosis and risk assessment for treatment decisions.
• Secondary thrombocytosis is common and usually reactive, with prophylaxis reserved for high-risk cases.
• Further research into the specific genetic and molecular underpinnings of childhood thrombocytosis is warranted.